Table 2 Primers used in this study
Primer name | Sequence (5′ → 3′) | Purpose |
|---|---|---|
hrdB F | GCATGCTCTTCCTGGACCTCAT | qPCR |
hrdB R | TGGAGAACTTGTAGCCCTTGGTGTA | qPCR |
hmpA F | AACAGTCCGTTCCCGTGGT | qPCR |
hmpA R | CGAAGAGCTTGCGGTAGAACAG | qPCR |
actII-ORF4 F | AAAGGAATATCGCGCACCTGGAAG | qPCR |
actII-ORF4 R | GTTCCGGAATCATCGGCCCTATTC | qPCR |
devR F | ACGACGAACCGGACATCACC | qPCR |
devR R | CGTCGTCGAAGGAGGTCAGC | qPCR |
mshA F | GTGAGCCAGTACGTCAGCAG | qPCR |
mshA R | AGCTCCACGATGTAGACGTTC | qPCR |
mshB F | TCGCGAAGGTCTACTGGAAC | qPCR |
mshB R | CCTTCTCGAACGGCAGTCC | qPCR |
mshC F | CGTACGACGCCACCCACAT | qPCR |
mshC R | TAGTGGACCTGCCGCTTGGT | qPCR |
mshD F | TTGACCGGCCTGGACCTG | qPCR |
mshD R | TGAGCGACCCCTGTTCGG | qPCR |
∆mshC upstream F | AAGCTTTAAACAGGCGTACAGACAGAAGAAAGA | Disruption |
∆mshC upstream R | GAATTCACCCCGATCGACAAGTACCG | Disruption |
∆mshC downstream F | GAATTCGCCGAACTGGGGAACGAG | Disruption |
∆mshC downstream R | AAGCTTCATGTCATGAGCCTAACCGGA | Disruption |
FRT drug resi F | CTCGAGAAGCTTATTCCGGGGATCCGTCGACC | Disruption |
FRT drug resi R | CTCGAGAAGCTTTGTAGGCTGGAGCTGCTTC | Disruption |
comp mshC F | CTCGAGGAATTCCGCTGAAGGACGGCGGCA | Complementation |
comp mshC R | CTCGAGAAGCTTTTACAGCGCCACGCCCAGC | Complementation |